ChiCTR-ONC-14004779
结束
他氟前列素滴眼液
化药
他氟前列素滴眼液
2014-06-10
/
-
對原發性開角型青光眼、 原發性閉角型青光眼、正常眼壓性青光眼或高眼壓病人施用0.0015% 他氟前列素 (Tafluprost) 滴眼液後的不良反應概況的研究
對原發性開角型青光眼、 原發性閉角型青光眼、正常眼壓性青光眼或高眼壓病人施用0.0015% 他氟前列素 (Tafluprost) 滴眼液後的不良反應概況的研究
To study on the Adverse Effect Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Normal Tension Glaucoma or Ocular Hypertension.
连续入组
其它
N/A
/
-
/
20
/
2014-06-21
1990-01-01
/
1) Patients diagnosed with primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG), normal tension glaucoma (NTG) or ocular hypertension (OHT); 2) Switching from latanoprost (other concomitant drugs should not be changed 1 month prior to the switch of medication and are continued during the treatment period); 3) Age between 18 to 70 years; 4) Those who can visit the clinic on the designated day as instructed by the physician.;
登录查看1) History of intraocular surgery or laser treatment during the three months before informed consent; 2) History of corneal refractive surgery; 3) History of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product; 4) Presence of any corneal disorder that may interfere with accurate IOP measurement using applanation tonometer; 5) Female patients who are pregnant, nursing or planning a pregnancy; 6) Patients who need to change their pretreating ophthalmic medications (other than latanoprost) during the study.;
登录查看Santen Pharmaceutical Co., Ltd.
/
diabetes 埃诺格鲁肽 SLIMMER
医药笔记2025-06-22
遗传性血管性水肿 III期 BD项目
美柏资本2025-06-22
ADA GIPR PCSK9
信达生物2025-06-22
diabetes 埃诺格鲁肽 内分泌学
先为达生物2025-06-22
PDL1 三阴性乳腺癌 atezolizumab
BioArtMED2025-06-21
EGFR 结直肠癌 JMT101
石药集团2025-06-21
糖尿病 GLP-1/GIP
恒瑞医药2025-06-21
肥胖 Wegovy
一度医药2025-06-21